Annual Shareholders Equity
$1.64 M
-$1.60 M-49.37%
December 1, 2023
Summary
- As of February 7, 2025, RNAZ annual stockholders equity is $1.64 million, with the most recent change of -$1.60 million (-49.37%) on December 1, 2023.
- During the last 3 years, RNAZ annual shareholders equity has risen by +$5.05 million (+148.14%).
- RNAZ annual shareholders equity is now -91.96% below its all-time high of $20.40 million, reached on December 31, 2021.
Performance
RNAZ Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$1.65 M
+$329.90 K+24.95%
September 1, 2024
Summary
- As of February 7, 2025, RNAZ quarterly stockholders equity is $1.65 million, with the most recent change of +$329.90 thousand (+24.95%) on September 1, 2024.
- Over the past year, RNAZ quarterly shareholders equity has dropped by -$2.79 million (-62.79%).
- RNAZ quarterly shareholders equity is now -92.86% below its all-time high of $23.16 million, reached on September 30, 2021.
Performance
RNAZ Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
RNAZ Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -49.4% | -62.8% |
| 3 y3 years | +148.1% | -92.9% |
| 5 y5 years | +247.8% | - |
RNAZ Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -92.0% | at low | -91.9% | +797.7% |
| 5 y | 5-year | -92.0% | +148.1% | -92.9% | +121.1% |
| alltime | all time | -92.0% | +148.1% | -92.9% | +121.1% |
TransCode Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.65 M(+24.9%) |
| Jun 2024 | - | $1.32 M(-71.2%) |
| Mar 2024 | - | $4.58 M(+179.4%) |
| Dec 2023 | $1.64 M(-49.4%) | $1.64 M(-63.0%) |
| Sep 2023 | - | $4.44 M(+112.2%) |
| Jun 2023 | - | $2.09 M(-983.7%) |
| Mar 2023 | - | -$236.80 K(-107.3%) |
| Dec 2022 | $3.24 M | $3.24 M(-60.7%) |
| Sep 2022 | - | $8.24 M(-33.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $12.43 M(-26.9%) |
| Mar 2022 | - | $17.00 M(-16.7%) |
| Dec 2021 | $20.40 M(-698.7%) | $20.40 M(-11.9%) |
| Sep 2021 | - | $23.16 M(-559.8%) |
| Jun 2021 | - | -$5.04 M(-35.8%) |
| Mar 2021 | - | -$7.85 M(+130.2%) |
| Dec 2020 | -$3.41 M(+207.1%) | - |
| Dec 2020 | - | -$3.41 M |
| Dec 2019 | -$1.11 M | - |
FAQ
- What is TransCode Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for TransCode Therapeutics?
- What is TransCode Therapeutics annual shareholders equity year-on-year change?
- What is TransCode Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly shareholders equity year-on-year change?
What is TransCode Therapeutics annual stockholders equity?
The current annual shareholders equity of RNAZ is $1.64 M
What is the all time high annual shareholders equity for TransCode Therapeutics?
TransCode Therapeutics all-time high annual stockholders equity is $20.40 M
What is TransCode Therapeutics annual shareholders equity year-on-year change?
Over the past year, RNAZ annual stockholders equity has changed by -$1.60 M (-49.37%)
What is TransCode Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of RNAZ is $1.65 M
What is the all time high quarterly shareholders equity for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly stockholders equity is $23.16 M
What is TransCode Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, RNAZ quarterly stockholders equity has changed by -$2.79 M (-62.79%)